Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Instil Bio Inc has a consensus price target of $90.75 based on the ratings of 7 analysts. The high is $180 issued by Baird on September 16, 2024. The low is $6 issued by Truist Securities on April 5, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on September 11, 2025, August 27, 2025, and August 15, 2025, respectively. With an average price target of $125 between HC Wainwright & Co., there's an implied 1504.62% upside for Instil Bio Inc from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for Instil Bio (NASDAQ:TIL) was reported by HC Wainwright & Co. on January 7, 2026. The analyst firm set a price target for $0.00 expecting TIL to fall to within 12 months (a possible -100.00% downside). 8 analyst firms have reported ratings in the last year.
The latest analyst rating for Instil Bio (NASDAQ:TIL) was provided by HC Wainwright & Co., and Instil Bio downgraded their neutral rating.
The last upgrade for Instil Bio Inc happened on January 7, 2025 when Jefferies raised their price target to $52. Jefferies previously had a hold for Instil Bio Inc.
The last downgrade for Instil Bio Inc happened on January 7, 2026 when HC Wainwright & Co. changed their price target from N/A to N/A for Instil Bio Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Instil Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Instil Bio was filed on January 7, 2026 so you should expect the next rating to be made available sometime around January 7, 2027.
While ratings are subjective and will change, the latest Instil Bio (TIL) rating was a downgraded with a price target of $0.00 to $0.00. The current price Instil Bio (TIL) is trading at is $7.79, which is out of the analyst’s predicted range.